Skip to content

Admin

Blog Post by Admin

Presentation
Apr 27, 2022

Utility Assessments in Synthetic Data

Start Reading
Blog
Apr 19, 2022

RWE Guidance: NICE’s RWE Framework

This month, the UK’s National Institute for Health and Care Excellence (NICE) released ...
Start Reading
Publication
Apr 15, 2022

Utility Metrics for Evaluating Synthetic Health Data Generation Methods: Validation Study

Start Reading
Presentation
Mar 30, 2022

Managing and Regulating Privacy Risks in Synthetic Data

Start Reading
Presentation
Feb 9, 2022

Synthetic Data Generation 101

Start Reading
Blog
Feb 9, 2022

Aetion’s comments to FDA on data standards for RWD in drug and biological product submissions

Last week, Aetion submitted a letter to FDA commenting on the Agency’s recent draft ...
Start Reading
Blog
Feb 3, 2022

Aetion’s comments to FDA on electronic health records and claims to support regulatory decisions

Last week, Aetion submitted a letter to FDA commenting on the Agency’s recent draft ...
Start Reading
Blog
Jan 28, 2022

Understanding propensity score weighting methods

Oftentimes researchers want to compare two medications—an existing medication to a newly ...
Start Reading
Blog
Jan 4, 2022

Why we acquired synthetic data pioneer Replica Analytics

The potential for real-world evidence (RWE) to improve patient lives and better protect ...
Start Reading
Blog
Dec 22, 2021

What I learned from former FDA leaders during Aetion’s RWE Summit

Aetion hosted our annual RWE Summit in New York last month, and I am still inspired by ...
Start Reading
Blog
Dec 21, 2021

Research spotlight: Using RWE to characterize prescription opioid dispensing patterns after surgical abortion

Over 800,000 abortions occur annually in the United States, the majority of which are ...
Start Reading
Presentation
Dec 1, 2021

Generating Synthetic Longitudinal Data

Start Reading
Blog
Nov 18, 2021

What industry can learn from RWE demonstration projects

As global regulatory and health technology assessment (HTA) bodies continue to iterate on ...
Start Reading
Blog
Nov 12, 2021

RWE guidance watch: EMA real world evidence guidance on registry-based studies

UPDATE: As of November 2021, EMA has now issued its final guideline on registry-based ...
Start Reading
Blog
Oct 29, 2021

COVID-19 vaccine rollout shows real-world evidence was ready for the spotlight

Just 10 months since administration of the first COVID-19 vaccine dose, hundreds of ...
Start Reading
Presentation
Oct 27, 2021

Synthetic Data Generation for Rare Disease Research

Start Reading
Blog
Sep 30, 2021

Join primary and real-world data to generate patient-relevant RWE across the product lifecycle: Q&A with Dr. Javier Jimenez of Syneos Health

Understanding how medical interventions impact patients has always been a top priority ...
Start Reading
Presentation
Sep 22, 2021

Measuring Re-identification Risk for Synthetic and Anonymized Data

Start Reading
Presentation
Sep 13, 2021

Synthetic Data

Start Reading
Blog
Sep 9, 2021

ICPE Research Spotlight 2021: Part II: Forging methods to advance principled database epidemiology

This year at ICPE All Access, Aetion’s scientific research was represented across ...
Start Reading
Presentation
Sep 2, 2021

Practical Mechanisms for Generating Anonymous Data

Start Reading
Presentation
Sep 1, 2021

Ten Recommendations For Regulating De-identification

Start Reading
Blog
Aug 26, 2021

ICPE Research Spotlight 2021: Part I: Findings from Aetion-FDA research collaboration to advance understanding of COVID-19 with RWE

This year at ICPE All Access, Aetion’s scientific research is represented across ...
Start Reading
Blog
Aug 26, 2021

RWE to inform value decision-making: Learnings from ICER’s 24-month reassessment pilot

In its 2020 Value Assessment Framework, the Institute of Clinical and Economic Review ...
Start Reading